
Charles River Laboratories International, Inc.: updates and filings
Price
$314.32
November 20, 2026Market cap $15.5B
What Ploutos Investor adds for Charles River Laboratories International
Part of Ploutos Investor, €9.99 a month
- The full history: 17 fiscal years, from FY2009
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- Most of the reported profit is a tax credit, not money earned from customers. We leave out the P/E and the earnings growth, which would not compare with a company that paid tax.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 4, 2026next Feb 3, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
August 2026
May 2026
February 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 16, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Nov 10, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 9, 2026Regulation FD disclosureForm8-K
- Nov 5, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 4, 2026Quarterly reportfor the period to Sep 26, 2026Form10-Q
- Nov 4, 2026Results of operationsForm8-K
- Sep 24, 2026Regulation FD disclosureForm8-K
- Sep 8, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 13, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Aug 6, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 5, 2026Quarterly reportfor the period to Jun 27, 2026Form10-Q
- Aug 5, 2026Results of operationsForm8-K
- May 11, 2026Officer or director change, shareholder voteForm8-K
- May 11, 2026Conflict minerals reportFormSD
- May 7, 2026Shares registered for employeesFormS-8
- May 7, 2026Quarterly reportfor the period to Mar 28, 2026Form10-Q
- May 7, 2026Results of operationsForm8-K
- May 6, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 6, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Apr 29, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Mar 31, 2026Annual report to shareholdersfor the period to Dec 27, 2025FormARS
- Mar 31, 2026Annual meeting proxy statementFormDEF 14A
- Mar 26, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Feb 25, 2026Regulation FD disclosureForm8-K
- Feb 18, 2026Officer or director changeForm8-K
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 16, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Nov 10, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 9, 2026 | 8-K | Regulation FD disclosure | Document |
| Nov 5, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 4, 2026 | 10-Q | Quarterly reportfor the period to Sep 26, 2026 | Document |
| Nov 4, 2026 | 8-K | Results of operations | Document |
| Sep 24, 2026 | 8-K | Regulation FD disclosure | Document |
| Sep 8, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 13, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Aug 6, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 5, 2026 | 10-Q | Quarterly reportfor the period to Jun 27, 2026 | Document |
| Aug 5, 2026 | 8-K | Results of operations | Document |
| May 11, 2026 | 8-K | Officer or director change, shareholder vote | Document |
| May 11, 2026 | SD | Conflict minerals report | Document |
| May 7, 2026 | S-8 | Shares registered for employees | Document |
| May 7, 2026 | 10-Q | Quarterly reportfor the period to Mar 28, 2026 | Document |
| May 7, 2026 | 8-K | Results of operations | Document |
| May 6, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 6, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Apr 29, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Mar 31, 2026 | ARS | Annual report to shareholdersfor the period to Dec 27, 2025 | Document |
| Mar 31, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Mar 26, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Feb 25, 2026 | 8-K | Regulation FD disclosure | Document |
| Feb 18, 2026 | 8-K | Officer or director change | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Dec 8, 1999. Of its note and share prospectuses (424B, FWP), the newest 40 of 47.
The full analysis
What do Charles River Laboratories International's filings show?
The filings are where every one of Charles River Laboratories International's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.